Sign inJoin waitlistJoin the waitlist

Tapan Kadia

Training Program Director · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

Training · University of Texas M D Anderson Cancer Center
Present
University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2005–2008
Baylor College of Medicine Affiliated Hospitals
2001–2004
Rutgers, Robert Wood Johnson Medical School
1997–2001

Research

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
Cancer Discovery · 2016 · 940 citations
Acute myeloid leukemia: current progress and future directions
Review · Blood Cancer Journal · 2021 · 639 citations
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Cancer Discovery · 2019 · 474 citations

Hagop Kantarjian
438 papers
Elias Jabbour
356 papers
Naval Daver
350 papers · 1 as a fellow
Guillermo Garcia-Manero
349 papers
Courtney DiNardo
322 papers
GB
Gautam Borthakur
316 papers
Nicholas Short
234 papers · 18 as a fellow
Marina Konopleva
223 papers
Naveen Pemmaraju
213 papers
KS
Koji Sasaki
190 papers · 24 as a fellow
Jorge Cortes
183 papers
Nitin Jain
141 papers

Clinical trials

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2026–2031
Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
Principal investigator · Recruiting · Phase 1, Phase 2
M.D. Anderson Cancer Center
2026–2031
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Principal investigator · Recruiting · Phase 1
M.D. Anderson Cancer Center
2021–2026
Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Principal investigator · Active not recruiting · Phase 1
M.D. Anderson Cancer Center
2021–2027